Pre-made Reslizumab benchmark antibody ( Whole mAb, anti-IL5 therapeutic antibody, Anti-EDF/IL-5/TRF Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Reslizumab biosimilar, Whole mAb, Anti-IL5 Antibody: Anti-EDF/IL-5/TRF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Reslizumab is a humanized monoclonal antibody against human interleukin-5 (IL-5). Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. By binding to human IL-5, it blocks its biological function; consequently survival and activity of eosinophils are reduced. The benefits with reslizumab are its ability to reduce the exacerbation rate and improve lung function and asthma-related quality of life in patients with severe eosinophilic asthma (with blood eosinophil count ≥ 400 cells/μL) and with at least one previous asthma exacerbation in the preceding year. The most common side effects are increased blood creatine phosphokinase, myalgia and anaphylactic reactions.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-479-1mg	1mg	3090
GMP-Bios-ab-479-10mg	10mg	Inquiry
GMP-Bios-ab-479-100mg	100mg	Inquiry
GMP-Bios-ab-479-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Reslizumab biosimilar, Whole mAb, Anti-IL5 Antibody: Anti-EDF/IL-5/TRF therapeutic antibody
INN Name	Reslizumab
Target	IL5
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2001
Year Recommended	2002
Companies	Celltech R&D;Schering-Plough;Allergy and Asthma Clinical Research;Celltech R&D;Teva Pharmaceutical Industries
Conditions Approved	Asthma
Conditions Active	Sinusitis;Churg-Strauss syndrome
Conditions Discontinued	Oesophagitis
Development Tech	na